UNDER RULE 8.1

AbbVie Inc. - Form 8.1 - Dealings By Offerors, Offerees Or Parties Acting In Concert With Them For Themselves Or For Discretionary Clients

NORTH CHICAGO, Ill., April 2, 2020 /PRNewswire/ --

IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS
1. KEY INFORMATION
Name of person dealing  (Note 1)	Edward J. Rapp
Company dealt in	AbbVie Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2)	Common shares, par value $0.01 per share
Date of dealing	31 March 2020

2. INTERESTS AND SHORT POSITIONS
(a)  Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
	Long					Short
	Number			(%)		Number		(%)
(1) Relevant securities	33,537 Common Shares (0.00002%)
(2) Derivatives (other than options)	17,318 (0.00001) Stock Equivalent Units
(3) Options and agreements to purchase/sell	N/A
Total	50,855 (0.00003%)
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A
Class of relevant security:	Long				Short
	Number		(%)		Number		(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

3. DEALINGS  (Note 4)
(a)  Purchases and sales
Purchase/sale	Number of relevant securities		Price per unit  (Note 5)
(b)  Derivatives transactions (other than options transactions)
Product name, e.g. CFD		Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit (Note 5)
Stock Equivalent Units		Director fee credit to stock equivalent unit account	446	$76.19

(c)  Options transactions in respect of existing relevant securities
(i)  Writing, selling, purchasing or varying
Product name, e.g. call option	Writing, selling,  purchasing,  varying etc.		Number of securities  to which the option  relates  (Note 7)		Exercise  price	Type, e.g.  American,  European etc.	Expiry  date		Option money  paid/received  per unit  (Note 5)
(ii)  Exercising
Product name, e.g. call option		Number of securities		Exercise price per unit  (Note 5)

(d)  Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction  (Note 8)		Details	Price per unit (if applicable)  (Note 5)
4.  OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

Is a Supplemental Form 8 attached?  (Note 9)   YES/NO?
Date of disclosure	2 April 2020
Contact name	Steven L. Scrogham
Telephone number	847-938-6166
Name of offeree/offeror with which acting in concert	AbbVie Inc.
Specify category and nature of acting in concert status	Director of AbbVie Inc.

CONTACT: Adelle Infante, 1-847-938-8745